Tags : Baysient

Insights+ Key Biosimilars Events of February 2020

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency. Biosimilars are expected to be a cost-effective alternative to high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients. Hence providers are likely to adopt biosimilars “a reference product to biologics” possessing similar […]Read More

Baysient to Release iDose Software Technology Platform 1.0 to Reduce

The 12-month clinical validation study (NCT02453776) data demonstrated the reduction “switching” from lower cost infliximab to more expensive biologics by 66%. Also, similar studies are ongoing in 9 countries on 3 continents The results were already presented at ECCO, Copenhagen, Mar 2019 and DDW, San Diego, May 2019 and the Baysient pipeline includes CDS for […]Read More